Bloomberg Intelligence cover image

Novo Next-Generation Obesity Shot Falls Short of Lilly Rival

Bloomberg Intelligence

00:00

Why Lilly overtook Novo biologically

Sam discusses mechanistic choices—GIP/GLP-1 versus amylin—and how Lilly's risk paid off scientifically and commercially.

Play episode from 03:32
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app